Expense

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 25, 2024
Rated R, Fulvestrant, KICKSTART, Patient, Sale, G&A, Investment, Therapy, Anemia, Vomiting, Artificial intelligence, Effector, Research, Science, AML, Expense, Pembrolizumab, Breast cancer, Safety, Fatigue, PD-L1, Database, NSCLC, Associate, Cancer, University, PFS, Hematology, FDA, OS, Azacitidine, ZF, Administration, Assistant, MNK, Progression-free survival, COVID-19, Fast Track, Messenger, Cell, Nausea, Research and development, DARPA, Interval (mathematics), Pharmaceutical industry

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The primary analysis will reflect 37 PFS events, which provides approximately 80% power to detect a PFS hazard ratio of 0.65 at a p≤0.2.
  • Revenue: Revenue was zero for the quarter ended December 31, 2023, compared to approximately $0.7 million for the same quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $6.1 million for the quarter ended December 31, 2023, compared to $6.6 million for the same quarter of 2022.
  • The earn-out period expired in August 2023 resulting in a reduction of the corresponding earn-out liability to zero as of December 31, 2023.

YieldMax™ ETFs Announces Monthly Distributions on Ultra and Fund of Funds ETFs YMAX (31.21%) YMAG (34.26%)

Retrieved on: 
Wednesday, March 13, 2024
ETF, Risk, History, NAV, Capital gain, TRUST, Lovell Minnick Partners, Prospectus, YMAX, Investment, Expense, Security, Fund

“Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.

Key Points: 
  • “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Each Underlying YieldMax™ ETF may actively and frequently trade all or a significant portion of the Underlying YieldMax™ ETF’s holdings.

Altus Power, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Other Energy, Environment, Utilities, Alternative Energy, Green Technology, Energy, Equipment, Growth, ARR, Partnership, Disposal, Accounting, Acquisition, Form 10-K, Depreciation, Expense, Bank statement, Interest expense, ASC, Vitol, GAAP, REC, Alignment, Retirement, Entity, PPA, Accretion expense, NMCA, Professional, Mergers and acquisitions

Altus Power, Inc. (NYSE: AMPS) (“Altus Power” or the “Company”), the largest commercial scale provider of clean, electric power, today announced its financial results for fourth quarter and full year 2023.

Key Points: 
  • Altus Power, Inc. (NYSE: AMPS) (“Altus Power” or the “Company”), the largest commercial scale provider of clean, electric power, today announced its financial results for fourth quarter and full year 2023.
  • Operating revenues during the fourth quarter of 2023 totaled $34.2 million, compared to $26.8 million during the same period of 2022, an increase of 28%.
  • Fourth quarter 2023 GAAP net loss totaled $40.0 million, compared to net income of $67.1 million for the same period last year.
  • Adjusted EBITDA* during the fourth quarter of 2023 was $17.3 million, compared to $16.6 million for the fourth quarter of 2022, a 5% increase.

LiqTech International Announces Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
MEG, Growth, Swimming, Convertible, COVID-19, DPF, Sale, Expense, O&G, Investment, Water, Depreciation

BALLERUP, Denmark, March 21, 2024 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.

Key Points: 
  • BALLERUP, Denmark, March 21, 2024 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.
  • Received order for the first U.S.-based oil & gas produced water order as part of new distribution agreement with Razorback Direct.
  • New orders for DPFs have increased 11% in the first quarter of 2024 compared to the same period in 2023.
  • The Company expects revenue in the first quarter of 2024 to be between $4.1 million and $4.3 million.

EQS-News: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024
Janus, Psoriasis, Research, Webcast, German, MRI, General assembly, Biotechnology, Calcium, Expense, Regeneration, Capital punishment, SIRT6, Conference, Biomarker, AFL, Patent, PMS, Histology, Clinical trial, Investment, Ulcerative colitis, Magnetic resonance imaging, SPMS, Research and development, Multiple sclerosis, UC, Administration, Patient, Disease, RMS, Pharmaceutical industry

The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).
  • The results demonstrated meaningful improvements over placebo in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

YieldMax™ Launches the Ultra Option Income Strategy ETF ULTY

Retrieved on: 
Thursday, February 29, 2024
YMAX, GOOY, Prospectus, Expense, NAV, ETF, Fund, Capital gain, Financial adviser

1 All YieldMax™ ETFs shown in the table above (except YMAX and YMAG) have a gross expense ratio of 0.99%.

Key Points: 
  • 1 All YieldMax™ ETFs shown in the table above (except YMAX and YMAG) have a gross expense ratio of 0.99%.
  • The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.
  • The Distribution Rate represents a single distribution from the ETF and does not represent its total return.
  • Such potential losses may not be offset by income received by the ETF.

YieldMax™ Launches Option Income Strategy ETF on MicroStrategy (MSTR)

Retrieved on: 
Thursday, February 22, 2024
GOOY, Expense, NAV, ETF, Fund, Capital gain, YMAX, Financial adviser

The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.

Key Points: 
  • The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.
  • The Distribution Rate represents a single distribution from the ETF and does not represent its total return.
  • 3 The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended January 31, 2024, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.
  • Such potential losses may not be offset by income received by the ETF.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
Health, Stem Cells, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Spinal cord, University, CIRM, Roche, Delivery, Interest, Expense, Partnership, Food, Inda, Genentech, Geographic atrophy, Therapy, Webcast, AMD, Patient, Drug discovery, Congress, Survival, G&A, IND, Trial of the century, Research, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

Kontoor Brands Reports 2023 Fourth Quarter and Full Year Results; Provides 2024 Outlook and Announces Project Jeanius Global Transformation

Retrieved on: 
Wednesday, February 28, 2024
Fashion, Online Retail, Retail, Manufacturing, Specialty, Textiles, Lee, ERP, International, Expense, Kontoor Brands, POS, Forecasting, Investment, Share repurchase, Wrangler, Digital, Growth, Capital expenditure, Female, Line of credit, Ratio, United States Customs Service, GAAP, KTB, Administration, Jeanius, EPS, Internet, Environment, DTC, Music

“Our POS performance in the U.S. outpaced shipments in the fourth quarter and resulted in continued market share gains.

Key Points: 
  • “Our POS performance in the U.S. outpaced shipments in the fourth quarter and resulted in continued market share gains.
  • Selling, General & Administrative (SG&A) expenses were $204 million or 30.5 percent of revenue on a reported basis in the fourth quarter.
  • The Company anticipates the impact from Project Jeanius to begin in the fourth quarter of 2024, with more significant benefits expected in 2025 and 2026.
  • Kontoor Brands will host its fourth quarter and full year 2023 conference call beginning at 8:30 a.m. Eastern Time today, February 28, 2024.

Eighth Annual State of the Data Center Industry Report Reveals How Power Design and AI Demand Has Forever Changed the Industry

Retrieved on: 
Tuesday, February 20, 2024
Professional Services, Data Management, Data Analytics, Technology, Software, Networks, Artificial Intelligence, Knowledge, Cloud, Artificial intelligence, AI, Traction, Capital expenditure, Water, Growth, Exhibition, ITSM, Data center, Expense, OPEX, Update, Data, CAPEX, Security, Research, Wind

AFCOM , the leading membership association for data center professionals, and Data Center World , the leading global conference for data center facilities and IT professionals, today announce the results of the eighth annual State of the Data Center industry report.

Key Points: 
  • AFCOM , the leading membership association for data center professionals, and Data Center World , the leading global conference for data center facilities and IT professionals, today announce the results of the eighth annual State of the Data Center industry report.
  • The report, which has been a fixture at the annual Data Center World industry conference, continues to capture the relentless pace of change in the data center industry.
  • As AI requirements grow, there has been a significant surge in demand, with a mounting focus on capacity to meet higher-density data center requirements.
  • Data Center World 2024 takes place April 15-18 in Washington, D.C. To register to attend Data Center World, click here .